Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cervical Cancer - Pipeline Review, H2 2018, provides an overview of the Cervical Cancer (Oncology) pipeline landscape.
Cervical cancer occurs when abnormal cells on the cervix grow out of control. Symptoms include abnormal vaginal bleeding, such as bleeding after sex (vaginal intercourse), bleeding after menopause, bleeding and spotting between periods, and having longer or heavier (menstrual) periods than usual. Risk factors include human papillomavirus or HPV infections, smoking, weakened immune system, Chlamydia infection, overweight and used of intrauterine device (IUD). Treatment options include surgery, radiation therapy, chemotherapy or a combination of methods.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cervical Cancer - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Cervical Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Cervical Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Cervical Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 7, 59, 47, 3, 41, 8 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 7, 1, 11 and 4 molecules, respectively.
Cervical Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Cervical Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Cervical Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cervical Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cervical Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Cervical Cancer (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cervical Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cervical Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
Table of Contents 2
Introduction 7
Cervical Cancer - Overview 8
Cervical Cancer - Therapeutics Development 9
Cervical Cancer - Therapeutics Assessment 35
Cervical Cancer - Companies Involved in Therapeutics Development 51
Cervical Cancer - Drug Profiles 102
Cervical Cancer - Dormant Projects 986
Cervical Cancer - Discontinued Products 993
Cervical Cancer - Product Development Milestones 994
Appendix 1005
List of Tables
Number of Products under Development for Cervical Cancer, H2 2018 29
Number of Products under Development by Companies, H2 2018 31
Number of Products under Development by Universities/Institutes, H2 2018 39
Products under Development by Companies, H2 2018 42
Products under Development by Universities/Institutes, H2 2018 53
Number of Products by Stage and Target, H2 2018 56
Number of Products by Stage and Mechanism of Action, H2 2018 62
Number of Products by Stage and Route of Administration, H2 2018 68
Number of Products by Stage and Molecule Type, H2 2018 70
Cervical Cancer - Pipeline by 3SBio Inc, H2 2018 71
Cervical Cancer - Pipeline by Aadi Bioscience Inc, H2 2018 71
Cervical Cancer - Pipeline by AbbVie Inc, H2 2018 72
Cervical Cancer - Pipeline by Abion Inc, H2 2018 72
Cervical Cancer - Pipeline by Abivax SA, H2 2018 73
Cervical Cancer - Pipeline by Admedus Ltd, H2 2018 73
Cervical Cancer - Pipeline by Advaxis Inc, H2 2018 74
Cervical Cancer - Pipeline by Advenchen Laboratories LLC, H2 2018 74
Cervical Cancer - Pipeline by Agenus Inc, H2 2018 75
Cervical Cancer - Pipeline by Almac Discovery Ltd, H2 2018 75
Cervical Cancer - Pipeline by amcure GmbH, H2 2018 75
Cervical Cancer - Pipeline by Amgen Inc, H2 2018 76
Cervical Cancer - Pipeline by AntiCancer Inc, H2 2018 76
Cervical Cancer - Pipeline by Asana BioSciences LLC, H2 2018 77
Cervical Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2018 77
Cervical Cancer - Pipeline by AstraZeneca Plc, H2 2018 78
Cervical Cancer - Pipeline by Bayer AG, H2 2018 78
Cervical Cancer - Pipeline by BeiGene Ltd, H2 2018 79
Cervical Cancer - Pipeline by Biocon Ltd, H2 2018 79
Cervical Cancer - Pipeline by Bioleaders Corp, H2 2018 80
Cervical Cancer - Pipeline by Biomics Biotechnologies Co Ltd, H2 2018 80
Cervical Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2018 80
Cervical Cancer - Pipeline by Bristol-Myers Squibb Co, H2 2018 81
Cervical Cancer - Pipeline by Cancer Research Technology Ltd, H2 2018 82
Cervical Cancer - Pipeline by Celgene Corp, H2 2018 82
Cervical Cancer - Pipeline by Celleron Therapeutics Ltd, H2 2018 83
Cervical Cancer - Pipeline by Cellestia Biotech AG, H2 2018 83
Cervical Cancer - Pipeline by Clovis Oncology Inc, H2 2018 83
Cervical Cancer - Pipeline by Corvus Pharmaceuticals Inc, H2 2018 84
Cervical Cancer - Pipeline by Cotinga Pharmaceuticals Inc, H2 2018 84
Cervical Cancer - Pipeline by Cue Biopharma Inc, H2 2018 85
Cervical Cancer - Pipeline by CytomX Therapeutics Inc, H2 2018 85
Cervical Cancer - Pipeline by Cytori Therapeutics Inc, H2 2018 86
Cervical Cancer - Pipeline by CZ BioMed Corp, H2 2018 86
Cervical Cancer - Pipeline by Daewon Pharm Co Ltd, H2 2018 87
Cervical Cancer - Pipeline by Daiichi Sankyo Co Ltd, H2 2018 87
Cervical Cancer - Pipeline by DelMar Pharmaceuticals Inc, H2 2018 88
Cervical Cancer - Pipeline by Etubics Corp, H2 2018 88
Cervical Cancer - Pipeline by Eureka Therapeutics Inc, H2 2018 89
Cervical Cancer - Pipeline by EyeGene Inc, H2 2018 89
Cervical Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018 90
Cervical Cancer - Pipeline by FLX Bio Inc, H2 2018 90
Cervical Cancer - Pipeline by Forbius, H2 2018 90
Cervical Cancer - Pipeline by GamaMabs Pharma SA, H2 2018 91
Cervical Cancer - Pipeline by Gene Techno Science Co Ltd, H2 2018 91
Cervical Cancer - Pipeline by Genentech Inc, H2 2018 92
Cervical Cancer - Pipeline by Genetic Immunity Inc, H2 2018 92
Cervical Cancer - Pipeline by Genexine Inc, H2 2018 93
Cervical Cancer - Pipeline by Genmab A/S, H2 2018 93
Cervical Cancer - Pipeline by GlaxoSmithKline Plc, H2 2018 94
Cervical Cancer - Pipeline by Glycostem Therapeutics BV, H2 2018 94
Cervical Cancer - Pipeline by Gradalis Inc, H2 2018 94
Cervical Cancer - Pipeline by Immunitor Inc, H2 2018 95
Cervical Cancer - Pipeline by Immunomedics Inc, H2 2018 95
Cervical Cancer - Pipeline by IMV Inc, H2 2018 96
Cervical Cancer - Pipeline by Incyte Corp, H2 2018 96
Cervical Cancer - Pipeline by Innate Pharma SA, H2 2018 97
Cervical Cancer - Pipeline by InSight Biopharmaceuticals Ltd, H2 2018 97
Cervical Cancer - Pipeline by Iovance Biotherapeutics Inc, H2 2018 98
Cervical Cancer - Pipeline by ISA Pharmaceuticals BV, H2 2018 98
Cervical Cancer - Pipeline by JHL Biotech Inc, H2 2018 98
Cervical Cancer - Pipeline by Johnson & Johnson, H2 2018 99
Cervical Cancer - Pipeline by Juno Therapeutics Inc, H2 2018 99
Cervical Cancer - Pipeline by Karyopharm Therapeutics Inc, H2 2018 100
Cervical Cancer - Pipeline by Kite Pharma Inc, H2 2018 101
List of Figures
Number of Products under Development for Cervical Cancer, H2 2018 29
Number of Products under Development by Companies, H2 2018 30
Number of Products under Development by Universities/Institutes, H2 2018 39
Number of Products by Top 10 Targets, H2 2018 55
Number of Products by Stage and Top 10 Targets, H2 2018 55
Number of Products by Top 10 Mechanism of Actions, H2 2018 61
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018 61
Number of Products by Top 10 Routes of Administration, H2 2018 67
Number of Products by Stage and Top 10 Routes of Administration, H2 2018 67
Number of Products by Top 10 Molecule Types, H2 2018 69
Number of Products by Stage and Top 10 Molecule Types, H2 2018 69
